Recent Updates
Recently added Catalysts
PYPD Positive Sentiment

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Thursday, November 7, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: PolyPid Ltd. announced its participation in the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024, in New York. The company, which is focused on enhancing surgical outcomes, will engage in investor meetings at the event. PolyPid's lead product, D-PLEX100, is currently undergoing a Phase 3 clinical trial aimed at preventing surgical site infections following abdominal colorectal surgery. Additionally, the company is exploring OncoPLEX for treating solid tumors like glioblastoma in preclinical stages.
Price reaction · baseline $3.42 (2024-11-06 close) · hit after-hours · clean, no other PYPD news in the window
day 0 close
-0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a reputable conference indicates investor interest.
  • PolyPid is focused on improving surgical outcomes, which is a critical area.
  • Their proprietary PLEX technology holds potential for drug delivery.
  • The lead candidate D-PLEX100 is in an advanced Phase 3 trial.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+50%
120-day peak, hindsight
Typical move
4.8%
average across 4 past catalysts
Lead asset
D-PLEX
Phase 3 · Surgical Site Infection

Full Press Release Details

PETACH TIKVA, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in investor meetings at the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024, in New York, NY.
Investors interested in meeting with PolyPid should contact the conference representative directly.
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

Frequently Asked Questions

What is PolyPid Ltd. known for?

PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes.

When will PolyPid participate in investor meetings?

PolyPid will participate in the Craig-Hallum Conference on November 19, 2024.

What technology does PolyPid use for drug delivery?

PolyPid utilizes PLEX technology for controlled, prolonged-release drug delivery.

What is PolyPid's lead product candidate?

PolyPid's lead product candidate is D-PLEX100, targeting surgical site infections.

What is OncoPLEX being tested for?

OncoPLEX is in preclinical testing for treating solid tumors like glioblastoma.

ShareAdd on Google
Tags: PYPD Viatris Investor Conferences Healthcare PolyPid surgical outcomes D-PLEX100 Alpha Select Conference
Last updated: Nov 7, 2024

Biotech snapshot

Lead asset
D-PLEXPhase 3
Surgical Site Infection →

Catalyst track record

+50%
best trade around PYPD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PYPD.

See every catalyst's timing & PoA →